US2021252147A1PendingUtilityA1

VEGF Antagonist Formulations

80
Assignee: REGENERON PHARMAPriority: Mar 25, 2005Filed: May 4, 2021Published: Aug 19, 2021
Est. expiryMar 25, 2025(expired)· nominal 20-yr term from priority
Inventors:Daniel DixKelly FryeSusan Kautz
A61K 9/08A61K 9/0019A61K 38/17A61K 47/22A61K 39/39591A61K 31/4172A61K 47/26A61K 47/183A61K 38/179A61P 43/00C07K 16/22C07K 2319/30A61K 47/12A61K 47/02A61P 9/00C07K 2318/20A61K 47/10A61K 38/16A61P 7/00A61K 9/19A61P 35/00C07K 14/71A61K 31/7012Y02A50/30
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Claims

exact text as granted — not AI-modified
1 .- 20 . (canceled) 
     
     
         21 . A vial comprising a formulation comprising:
 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4,   a buffer comprising histidine,   an organic co-solvent comprising polysorbate, and   a stabilizing agent comprising a sugar, an amino acid or both.   
     
     
         22 . The vial of  claim 21 , wherein said cosolvent comprises polysorbate 20. 
     
     
         23 . The vial of  claim 21 , wherein said buffer comprises 5-50 mM histidine. 
     
     
         24 . The vial of  claim 23 , wherein said sugar comprises a sugar selected from group consisting of dextrose, ribose, fructose, mannitol, inositol, sorbitol, trehalose, sucrose, and lactose. 
     
     
         25 . The vial of  claim 23 , wherein said sugar comprises sucrose, trehalose, or mannitol. 
     
     
         26 . The vial of  claim 25 , wherein said sugar comprises sucrose. 
     
     
         27 . The vial of  claim 26 , wherein said sugar comprises 5-30% sucrose. 
     
     
         28 . The vial of  claim 26 , wherein said sugar comprises 5-20% sucrose. 
     
     
         29 . The vial of  claim 28 , wherein said formulation further comprises a tonicity agent. 
     
     
         30 . The vial of  claim 29 , wherein said tonicity agent is sodium chloride. 
     
     
         31 . The vial of  claim 29 , wherein said tonicity agent is 40 mM sodium chloride. 
     
     
         32 . The vial of  claim 22 , wherein said formulation has a pH of 6.0-6.5. 
     
     
         33 . The vial of  claim 32 , wherein said formulation has a pH of 6.2. 
     
     
         34 . The vial of  claim 32 , wherein said formulation has a pH of 6.5. 
     
     
         35 . The vial of  claim 32 , wherein said sugar comprises trehalose. 
     
     
         36 . The vial of  claim 32 , wherein said buffer comprises 10 mM histidine. 
     
     
         37 . The vial of  claim 21 , wherein said formulation comprises 40 mg/ml of said VEGF antagonist fusion protein. 
     
     
         38 . The vial of  claim 37 , wherein said cosolvent comprises polysorbate 20. 
     
     
         39 . The vial of  claim 38 , wherein said buffer comprises 5-50 mM histidine. 
     
     
         40 . The vial of  claim 39 , wherein said sugar comprises a sugar selected from group consisting of dextrose, ribose, fructose, mannitol, inositol, sorbitol, trehalose, sucrose, and lactose. 
     
     
         41 . The vial of  claim 39 , wherein said sugar comprises sucrose, trehalose, or mannitol. 
     
     
         42 . The vial of  claim 39 , wherein said sugar comprises sucrose. 
     
     
         43 . The vial of  claim 42 , wherein said sugar comprises 5-30% sucrose. 
     
     
         44 . The vial of  claim 42 , wherein said sugar comprises 5-20% sucrose. 
     
     
         45 . The vial of  claim 44 , wherein said formulation further comprises a tonicity agent. 
     
     
         46 . The vial of  claim 45 , wherein said tonicity agent is sodium chloride. 
     
     
         47 . The vial of  claim 45 , wherein said tonicity agent is 40 mM sodium chloride. 
     
     
         48 . The vial of  claim 41 , wherein said formulation has a pH of 6.0-6.5. 
     
     
         49 . The vial of  claim 48 , wherein said formulation has a pH of 6.2. 
     
     
         50 . The vial of  claim 48 , wherein said formulation has a pH of 6.5. 
     
     
         51 . The vial of  claim 48 , wherein said sugar comprises trehalose. 
     
     
         52 . The vial of  claim 49  wherein said buffer comprises 10 mM histidine. 
     
     
         53 . A pre-filled syringe comprising a formulation comprising:
 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4,   a buffer comprising histidine,   an organic co-solvent comprising polysorbate, and   a stabilizing agent comprising a sugar, an amino acid or both.   
     
     
         54 . The pre-filled syringe of  claim 53 , wherein said cosolvent comprises polysorbate 20. 
     
     
         55 . The pre-filled syringe of  claim 53 , wherein said buffer comprises 5-50 mM histidine. 
     
     
         56 . The pre-filled syringe of  claim 55 , wherein said sugar comprises a sugar selected from group consisting of dextrose, ribose, fructose, mannitol, inositol, sorbitol, trehalose, sucrose, and lactose. 
     
     
         57 . The pre-filled syringe of  claim 55 , wherein said sugar comprises sucrose, trehalose, or mannitol. 
     
     
         58 . The pre-filled syringe of  claim 57 , wherein said sugar comprises sucrose. 
     
     
         59 . The pre-filled syringe of  claim 58 , wherein said sugar comprises 5-30% sucrose. 
     
     
         60 . The pre-filled syringe of  claim 58 , wherein said sugar comprises 5-20% sucrose. 
     
     
         61 . The pre-filled syringe of  claim 60 , wherein said formulation further comprises a tonicity agent. 
     
     
         62 . The pre-filled syringe of  claim 61 , wherein said tonicity agent is sodium chloride. 
     
     
         63 . The pre-filled syringe of  claim 61 , wherein said tonicity agent is 40 mM sodium chloride. 
     
     
         64 . The pre-filled syringe of  claim 54 , wherein said formulation has a pH of 6.0-6.5. 
     
     
         65 . The pre-filled syringe of  claim 64 , wherein said formulation has a pH of 6.2. 
     
     
         66 . The pre-filled syringe of  claim 64 , wherein said formulation has a pH of 6.5. 
     
     
         67 . The pre-filled syringe of  claim 64 , wherein said sugar comprises trehalose. 
     
     
         68 . The pre-filled syringe of  claim 64 , wherein said buffer comprises 10 mM histidine. 
     
     
         69 . The pre-filled syringe of  claim 53 , wherein said formulation comprises 40 mg/ml of said VEGF antagonist fusion protein. 
     
     
         70 . The pre-filled syringe of  claim 69 , wherein said cosolvent comprises polysorbate 20. 
     
     
         71 . The pre-filled syringe of  claim 70 , wherein said buffer comprises 5-50 mM histidine. 
     
     
         72 . The pre-filled syringe of  claim 71 , wherein said sugar comprises a sugar selected from group consisting of dextrose, ribose, fructose, mannitol, inositol, sorbitol, trehalose, sucrose, and lactose. 
     
     
         73 . The pre-filled syringe of  claim 71 , wherein said sugar comprises sucrose, trehalose, or mannitol. 
     
     
         74 . The pre-filled syringe of  claim 71 , wherein said sugar comprises sucrose. 
     
     
         75 . The pre-filled syringe of  claim 74 , wherein said sugar comprises 5-30% sucrose. 
     
     
         76 . The pre-filled syringe of  claim 74 , wherein said sugar comprises 5-20% sucrose. 
     
     
         77 . The pre-filled syringe of  claim 76 , wherein said formulation further comprises a tonicity agent. 
     
     
         78 . The pre-filled syringe of  claim 77 , wherein said tonicity agent is sodium chloride. 
     
     
         79 . The pre-filled syringe of  claim 77 , wherein said tonicity agent is 40 mM sodium chloride. 
     
     
         80 . The pre-filled syringe of  claim 73 , wherein said formulation has a pH of 6.0-6.5. 
     
     
         81 . The pre-filled syringe of  claim 80 , wherein said formulation has a pH of 6.2. 
     
     
         82 . The pre-filled syringe of  claim 80 , wherein said formulation has a pH of 6.5. 
     
     
         83 . The pre-filled syringe of  claim 80 , wherein said sugar comprises trehalose. 
     
     
         84 . The pre-filled syringe of  claim 81 , wherein said buffer comprises 10 mM histidine.

Join the waitlist — get patent alerts

Track US2021252147A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.